-
Capital, M&A & Industry Strategy1 month agoSTAT+: Flagship gets a Pentagon contract
Biotech investment firm Flagship Pioneering has been awarded a contract by the Department of Defense to advance countermeasure technologies against biological threats.
-
Capital, M&A & Industry Strategy1 month agoNovo talks up drug launches in effort to win back investors
At a “capital markets day” in London, executives outlined a roadmap to better compete with key rival Eli Lilly and soon bring forth several multibillion-dollar products.
-
Capital, M&A & Industry Strategy1 month agoBasecamp Research Raise $140M Series C Financing Toward Advancing AI-Designed Drugs
According to Basecamp, EDEN offers the ability to design long and complex DNA sequences with large serine recombinases capable of delivering those sequences precisely. The post...
-
Capital, M&A & Industry Strategy1 month ago“An open and collaborative culture”: what makes Sweden attractive for life sciences
The life science sector is a key export industry in Sweden. A culture of collaboration has often been attributed to the progress. The post “An open...
-
Capital, M&A & Industry Strategy1 month agoNovo’s turnaround plan, weight loss wins, Ultragenyx’s Sanfilippo approval, IPO blitz
Novo plans to hit $23B in revenue by 2035, has further reduced its workforce by 4,000 and is boosting manufacturing capacity for its Wegovy pill, but...
-
Capital, M&A & Industry Strategy1 month agoBoomRay and Novartis Pharma sign $900m deal for radioligand therapy
The agreement includes an upfront payment, as well as potential development, regulatory, and sales milestone payments for BoomRay, along with possible royalties on future global net...
-
Capital, M&A & Industry Strategy1 month agoBoehringer and Envisagenics to develop precision cancer therapies
Under the agreement, Envisagenics is set to receive more than $1bn through potential payments. These include an upfront sum, research funding, option fees, and milestones related...
-
Capital, M&A & Industry Strategy1 month agoBoehringer adds $250M to value of Variant pact by expanding into cardiovascular disease
Boehringer Ingelheim has dived deeper into its collaboration with Variant Bio by expanding the collaboration to cover cardiovascular disease to the tune of $250 million.
-
Capital, M&A & Industry Strategy1 month agoUK issues £45m funding call for research partnerships
The NIHR has revealed the first £45m in funding for projects that can bridge the translation gap in healthcare, focusing initially on community care.
-
Capital, M&A & Industry Strategy1 month ago
AstraZeneca recommits to youth health to dial funding past $100M
AstraZeneca has re-upped its UNICEF-partnered Young Health Programme, committing to a new five-year phase that will move total investment in the initiative above $100 million.
LncRNA SBF2-AS1 Worsens Heart Injury After Attack via miR-149-5p/PHLPP2 Axis
Stigmatizing language found in over half of primary care patient records
Research report: The Influence of Renal or Hepatic Impairment on the Pharmacokinetics of Iclepertin (BI 425809): Results from Two Phase I Open-Label, Non-randomised, Single Dose, Parallel Design Studies
Novartis buys Synnovation’s PI3Kα inhibitors for $3 billion
Novartis to pay $2B upfront to take next-gen PI3Kα inhibitor from Synnovation
